Zaryab Bacha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zaryab Bacha has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Abdul Rafay
Department of medicine, Islamic International Medical College, Rawalpindi, Pakistan
1 shared publicationAffan Masaud Mian
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
1 shared publicationAnne Tristan
Institute of Infectious Agents, National Reference Center for Staphylococci, Hospices Civils de Lyon, Lyon, France
1 shared publicationAurélie Portefaix
Clinical Investigation Center P-1407, Department of General Pediatrics
1 shared publicationBilal Wazir Khan
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
1 shared publicationIhtisham Ahmad
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
1 shared publication
Latest Publications
- 5 November 2025
- Published by Wolters Kluwer Health in Cardiology in Review
Axillary Versus Femoral Artery Cannulation in Type A Aortic Dissection: A Systematic Review and Meta-Analysis
Acute type A aortic dissection is a life-threatening condition requiring immediate surgical intervention. However, the optimal arterial cannulation site for cardiopulmonary bypass during surgery remains a subject of debate. Axillary cannulation (AXC) is thought to provide neuroprotective benefits due to antegrade perfusion, whereas femoral cannulation is more accessible but may be associated with increased risk of retrograde embolization and malperfusion. Conflicting findings from observational studies and large registries necessitate a comprehensive evidence synthesis. This systematic review and meta-analysis, conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines and registered with the International Prospective Register of Systematic Reviews, evaluated clinical trials and cohort studies comparing AXC and femoral cannulation in acute type A aortic dissection repair. Databases searched included PubMed, Embase, and Cochrane Library through July 2025. Primary outcomes were in-hospital and operative mortality, with secondary outcomes including stroke, neurological complications, renal failure, and operative parameters. Twenty studies encompassing over 5500 patients were included. AXC was significantly associated with reduced in-hospital mortality [risk ratio (RR) = 0.46], stroke (RR = 0.79), and neurological complications (RR = 0.72). No significant differences were observed in operative mortality, organ malperfusion, re-exploration for bleeding, or renal failure. Sensitivity analyses addressed heterogeneity and reinforced the robustness of effect estimates. Additionally, AXC showed advantages in intensive care unit (ICU) stay and operative metrics, such as cardiopulmonary bypass time and circulatory arrest duration. These findings support AXC as a favorable approach when anatomically and technically feasible, particularly in centers equipped for antegrade cerebral perfusion. However, high-quality randomized controlled trials are required to validate these observations and guide definitive clinical practice.
- 5 November 2025
- Published by Wolters Kluwer Health in Cardiology in Review
Axillary Versus Femoral Artery Cannulation in Type A Aortic Dissection: A Systematic Review and Meta-Analysis
Acute type A aortic dissection is a life-threatening condition requiring immediate surgical intervention. However, the optimal arterial cannulation site for cardiopulmonary bypass during surgery remains a subject of debate. Axillary cannulation (AXC) is thought to provide neuroprotective benefits due to antegrade perfusion, whereas femoral cannulation is more accessible but may be associated with increased risk of retrograde embolization and malperfusion. Conflicting findings from observational studies and large registries necessitate a comprehensive evidence synthesis. This systematic review and meta-analysis, conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines and registered with the International Prospective Register of Systematic Reviews, evaluated clinical trials and cohort studies comparing AXC and femoral cannulation in acute type A aortic dissection repair. Databases searched included PubMed, Embase, and Cochrane Library through July 2025. Primary outcomes were in-hospital and operative mortality, with secondary outcomes including stroke, neurological complications, renal failure, and operative parameters. Twenty studies encompassing over 5500 patients were included. AXC was significantly associated with reduced in-hospital mortality [risk ratio (RR) = 0.46], stroke (RR = 0.79), and neurological complications (RR = 0.72). No significant differences were observed in operative mortality, organ malperfusion, re-exploration for bleeding, or renal failure. Sensitivity analyses addressed heterogeneity and reinforced the robustness of effect estimates. Additionally, AXC showed advantages in intensive care unit (ICU) stay and operative metrics, such as cardiopulmonary bypass time and circulatory arrest duration. These findings support AXC as a favorable approach when anatomically and technically feasible, particularly in centers equipped for antegrade cerebral perfusion. However, high-quality randomized controlled trials are required to validate these observations and guide definitive clinical practice.
- 22 July 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (12) , 1216-1221
Neonatal Staphylococcus aureus Bacteremia: A 12-Year Retrospective Study on Treatment Duration and Relapse
Background: Antibiotic therapy for neonatal Staphylococcus aureus bacteremia (NSAB) is recommended for at least 14 days. However, this recommendation is based on very limited data. This study aimed to compare NSAB relapses between patients treated for less than 14 days versus 14 days or more in neonatal intensive care units. Methods: This retrospective study was conducted in 3 neonatal intensive care units. All patients with a positive blood culture for S. aureus from January 2010 to December 2022 were included. Relapse was defined as the identification of S. aureus in a blood culture within 3 months after cessation of antibiotic therapy. Results: Of 169 patients with positive blood culture for S. aureus , 134 patients were included in the analysis. Fifteen (9%) were excluded because cultures were considered contamination, 19 (11%) because of death before completing treatment, and one because of missing data. The median gestational age was 28 weeks. One hundred patients (75%) had a central venous line. The median duration of antibiotic therapy was 8 days (interquartile range: 6–9) in the P = 0.775). Conclusions: In this cohort, no increased risk of NSAB relapse was observed with treatment durations of less than 14 days. Further trials are necessary to determine the optimal treatment duration for NSAB.
- 22 July 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (12) , 1216-1221
Neonatal Staphylococcus aureus Bacteremia: A 12-Year Retrospective Study on Treatment Duration and Relapse
Background: Antibiotic therapy for neonatal Staphylococcus aureus bacteremia (NSAB) is recommended for at least 14 days. However, this recommendation is based on very limited data. This study aimed to compare NSAB relapses between patients treated for less than 14 days versus 14 days or more in neonatal intensive care units. Methods: This retrospective study was conducted in 3 neonatal intensive care units. All patients with a positive blood culture for S. aureus from January 2010 to December 2022 were included. Relapse was defined as the identification of S. aureus in a blood culture within 3 months after cessation of antibiotic therapy. Results: Of 169 patients with positive blood culture for S. aureus , 134 patients were included in the analysis. Fifteen (9%) were excluded because cultures were considered contamination, 19 (11%) because of death before completing treatment, and one because of missing data. The median gestational age was 28 weeks. One hundred patients (75%) had a central venous line. The median duration of antibiotic therapy was 8 days (interquartile range: 6–9) in the P = 0.775). Conclusions: In this cohort, no increased risk of NSAB relapse was observed with treatment durations of less than 14 days. Further trials are necessary to determine the optimal treatment duration for NSAB.